Literature DB >> 31088840

The Metabolic Basis of Kidney Cancer.

W Marston Linehan1, Laura S Schmidt2,3, Daniel R Crooks2, Darmood Wei2, Ramaprasad Srinivasan2, Martin Lang2, Christopher J Ricketts2.   

Abstract

Kidney cancer is not a single disease but represents several distinct types of cancer that have defining histologies and genetic alterations and that follow different clinical courses and have different responses to therapy. Mutation of genes associated with kidney cancer, such as VHL, FLCN, TFE3, FH, or SDHB, dysregulates the tumor's responses to changes in oxygen, iron, nutrient, or energy levels. The identification of these varying genetic bases of kidney cancer has increased our understanding of the biology of this cancer, allowing the development of targeted therapies and the appreciation that it is a cancer driven by metabolic alterations. SIGNIFICANCE: Kidney cancer is a complex disease composed of different types of cancer that present with different histologies, clinical courses, genetic changes, and responses to therapy. This review describes the known genetic changes within kidney cancer, how they alter tumor metabolism, and how these metabolic changes can be therapeutically targeted. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31088840     DOI: 10.1158/2159-8290.CD-18-1354

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  58 in total

1.  A Three-microRNA Panel in Serum: Serving as a Potential Diagnostic Biomarker for Renal Cell Carcinoma.

Authors:  Guocheng Huang; Xinji Li; Zebo Chen; Jingyao Wang; Chunduo Zhang; Xuan Chen; Xiqi Peng; Kaihao Liu; Liwen Zhao; Yongqing Lai; Liangchao Ni
Journal:  Pathol Oncol Res       Date:  2020-06-18       Impact factor: 3.201

2.  Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer.

Authors:  Daniel R Crooks; Nunziata Maio; Martin Lang; Christopher J Ricketts; Cathy D Vocke; Sandeep Gurram; Sevilay Turan; Yun-Young Kim; G Mariah Cawthon; Ferri Sohelian; Natalia De Val; Ruth M Pfeiffer; Parthav Jailwala; Mayank Tandon; Bao Tran; Teresa W-M Fan; Andrew N Lane; Thomas Ried; Darawalee Wangsa; Ashkan A Malayeri; Maria J Merino; Youfeng Yang; Jordan L Meier; Mark W Ball; Tracey A Rouault; Ramaprasad Srinivasan; W Marston Linehan
Journal:  Sci Signal       Date:  2021-01-05       Impact factor: 8.192

Review 3.  Mitochondrial Metabolism as a Target for Cancer Therapy.

Authors:  Karthik Vasan; Marie Werner; Navdeep S Chandel
Journal:  Cell Metab       Date:  2020-07-14       Impact factor: 27.287

4.  Development of an Interferon Gamma Response-Related Signature for Prediction of Survival in Clear Cell Renal Cell Carcinoma.

Authors:  Lixiao Liu; Xuedan Du; Jintao Fang; Jinduo Zhao; Yong Guo; Ye Zhao; Chengyang Zou; Xiaojian Yan; Wenfeng Li
Journal:  J Inflamm Res       Date:  2021-09-27

5.  Evaluation of aminolevulinic acid-mediated protoporphyrin IX fluorescence and enhancement by ABCG2 inhibitors in renal cell carcinoma cells.

Authors:  Richard Howley; Matthew Mansi; Janhavi Shinde; Juliana Restrepo; Bin Chen
Journal:  J Photochem Photobiol B       Date:  2020-09-05       Impact factor: 6.252

6.  Genome-wide mutation profiling and related risk signature for prognosis of papillary renal cell carcinoma.

Authors:  Chuanjie Zhang; Yuxiao Zheng; Xiao Li; Xin Hu; Feng Qi; Jun Luo
Journal:  Ann Transl Med       Date:  2019-09

7.  Obesity-Dependent Adipokine Chemerin Suppresses Fatty Acid Oxidation to Confer Ferroptosis Resistance.

Authors:  Sze Kiat Tan; Iqbal Mahmud; Flavia Fontanesi; Michelle Puchowicz; Chase K A Neumann; Anthony J Griswold; Rutulkumar Patel; Marco Dispagna; Hamzah H Ahmed; Mark L Gonzalgo; J Mark Brown; Timothy J Garrett; Scott M Welford
Journal:  Cancer Discov       Date:  2021-03-23       Impact factor: 39.397

Review 8.  A challenging frontier - the genomics and therapeutics of nonclear cell renal cell carcinoma.

Authors:  Hiren V Patel; Arnav Srivastava; Ramaprasad Srinivasan; Eric A Singer
Journal:  Curr Opin Oncol       Date:  2021-05-01       Impact factor: 3.645

9.  Stratification of patients with clear cell renal cell carcinoma to facilitate drug repositioning.

Authors:  Xiangyu Li; Woonghee Kim; Kajetan Juszczak; Muhammad Arif; Yusuke Sato; Haruki Kume; Seishi Ogawa; Hasan Turkez; Jan Boren; Jens Nielsen; Mathias Uhlen; Cheng Zhang; Adil Mardinoglu
Journal:  iScience       Date:  2021-06-12

10.  Increased CDC6 Expression Associates With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma.

Authors:  Yao Yicong; Yi Wang; Wu Denglong; Hu Baoying
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.